Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: Results from the BACH trial

Martin Möckel, Julia Searle, Oliver Hartmann, Stefan D. Anker, W. Frank Peacock, Alan H B Wu, Alan Maisel

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives To assess the value of mid-regional proadrenomedullin (MR-proADM) in guiding patient disposition from the emergency department (ED), as one of the key factors of hospital resource utilisation, in undifferentiated patients with acute dyspnoea. Methods We used clinical and outcome data from a large international biomarker study (BACH trial) and analysed data of all 1557 patients of the European and US sites presenting with acute dyspnoea. Patients were discharged or transferred from the ED to different levels of care (general ward, monitoring unit, intensive care unit). This original patient disposition was compared with the hypothetical disposition based on an adapted method of net reclassification improvement (NRI), which upgraded or downgraded patients from one level of care to the other based on the MR-proADM test result. Results MR-pro-ADM was significantly higher in patients who died during the follow-up than in survivors (p

Original languageEnglish
Pages (from-to)633-637
Number of pages5
JournalEmergency Medicine Journal
Volume30
Issue number8
DOIs
Publication statusPublished - Aug 2013

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Fingerprint Dive into the research topics of 'Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: Results from the BACH trial'. Together they form a unique fingerprint.

Cite this